NEW YORK (GenomeWeb) – Interpace Diagnostics said on Monday that it has entered into a purchase agreement with a single institutional investor to raise about $1.7 million in net proceeds in a direct stock offering.

Under the terms of the deal, the unnamed investor will purchase 2 million shares of Interpace's common stock at $.53 per share and 1.6 million prefunded warrants to purchase common stock at $.52 per share. The offering is anticipated to close on or about Dec. 22. Maxim Group acted as the exclusive placement agent for the offering.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.